Labopharm Reports Results for First Quarter F... ( - Once-Daily Tramadol Continues to G...)

Labopharm Reports Results for First Quarter Fiscal 2008

Date:5/8/2008

- Once-Daily Tramadol Continues to Gain Market Share in Europe and Canada;

Company Preparing NDA for Trazodone Contramid(R) Once-a-Day -

LAVAL, QC, May 8 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today reported its results for the first quarter ended March 31, 2008. All figures are in Canadian dollars unless otherwise stated.

"While we continue to make strong progress in the global commercialization of our once-daily tramadol product, we are preparing the New Drug Application for our second product, trazodone Contramid(R) once-a-day, for submission prior to year-end, and have initiated the Phase III clinical study for our third product, a twice-daily formulation of tramadol and acetaminophen," said James R. Howard-Tripp, President and Chief Executive Officer, Labopharm Inc. "In our global commercialization program for once-daily tramadol, our product has been launched in 10 countries, including Poland earlier this year, and is steadily gaining market(1) share in Europe(2) and Canada. In February, the latest month for which data is available, our product was the best selling once-daily tramadol product in four of the five largest European markets."

Mr. Howard-Tripp added, "We are encouraged by the positive Phase III results for trazodone Contramid(R) once-a-day. One of the greatest challenges in treating depression is that up to 50% of patients discontinue their medication within six months of initiating treatment and, therefore would benefit from an alternative treatment option. Patients need rapid improvement of their depressive symptoms and may experience insomnia and agitation. Our study demonstrated that trazodone Contramid(R) once-a-day was statistically superior to placebo by the end of the first week of treatment and was associated with an improvement in overall sleep quality. Accordingly, we are optimistic about the prospects for our formulation in the market for antidepressants."

Financial Summ
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. Labopharm Reports Results for Third Quarter Fiscal 2007
8. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
9. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
10. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
11. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone

Post Your Comments:

Labopharm Reports Results for First Quarter F...( - Once-Daily Tramadol Continues to G...),Health